Dana-farber Cancer Institute

This study tested a combination of two immunotherapy drugs, durvalumab and tremelimumab, in people with malignant pleural mesothelioma, a rare cancer of the lung lining. The 19 participants had already tried chemotherapy without success. The goal was to see if the drug pair could…

This study tested an experimental drug called BVD-523 in people with advanced uveal melanoma, a rare cancer that starts in the eye. The goal was to see if the drug could shrink tumors by blocking a specific protein that helps the cancer grow. The trial was small and ended early, …

This study tested a new drug, GDC-0084, combined with trastuzumab (Herceptin) in 17 people with HER2-positive breast cancer that had spread to the brain. The goal was to see if the combination could shrink or control brain tumors. The trial was stopped early, so results are limit…

This study tested a drug called neratinib, alone or with another drug (fulvestrant), in 21 people with a specific type of advanced breast cancer (HER2-positive and ER-positive). The goal was to see if the combination could slow cancer growth better than neratinib alone. The trial…

This study looked at adding the immunotherapy drug avelumab to standard radiation therapy for people with muscle-invasive bladder cancer who cannot take the chemotherapy drug cisplatin. The goal was to see if the combination could completely eliminate signs of cancer. The study e…

This study tested two immunotherapy drugs, ipilimumab and nivolumab, as the first treatment for people with advanced non-small cell lung cancer that had spread. The goal was to see how well the drugs worked and to find markers that predict response. Only 5 people enrolled before …